{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GLP-1+Therapy",
    "query": {
      "intervention": "GLP-1 Therapy"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 311,
    "total_pages": 32,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=GLP-1+Therapy&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-17T06:01:39.660Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07573163",
      "title": "Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mild Autonomous Cortisol Secretion (MACS)",
        "Adrenalectomy; Status"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Standard medical treatment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alaa Sada",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2026-07-27",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-09-17T06:01:39.660Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07573163"
    },
    {
      "nct_id": "NCT00798590",
      "title": "The Efficacy of Glucagon Like Peptide (GLP) - 1(7-36) Amide for Glycemic Control in Critically Ill Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Critically Ill",
        "Hypoglycemia"
      ],
      "interventions": [
        {
          "name": "Glucagon-Like Peptide-1",
          "type": "DRUG"
        },
        {
          "name": "Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "21 Years to 75 Years"
      },
      "enrollment_count": 19,
      "start_date": "2008-12",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-09-17T06:01:39.660Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00798590"
    },
    {
      "nct_id": "NCT03970044",
      "title": "Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Exenatide 2 MG",
          "type": "DRUG"
        },
        {
          "name": "Dapagliflozin 10 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Consano Clinical Research, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 67,
      "start_date": "2019-07-02",
      "completion_date": "2021-06-01",
      "has_results": false,
      "last_update_posted_date": "2021-08-30",
      "last_synced_at": "2026-09-17T06:01:39.660Z",
      "location_count": 1,
      "location_summary": "Shavano Park, Texas",
      "locations": [
        {
          "city": "Shavano Park",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03970044"
    },
    {
      "nct_id": "NCT05412004",
      "title": "Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Obstructive Sleep Apnea",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Tirzepatide",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 469,
      "start_date": "2022-06-21",
      "completion_date": "2024-03-29",
      "has_results": true,
      "last_update_posted_date": "2025-04-30",
      "last_synced_at": "2026-09-17T06:01:39.660Z",
      "location_count": 18,
      "location_summary": "Riverside, California • Brandon, Florida • Ocala, Florida + 15 more",
      "locations": [
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05412004"
    },
    {
      "nct_id": "NCT06273163",
      "title": "Identifying Strategies to Curtail Weight Regain After GLP-1 Receptor Agonist Treatment Cessation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Medically tailored meals",
          "type": "OTHER"
        },
        {
          "name": "Noom®",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Usual care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BEHAVIORAL"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2024-03-05",
      "completion_date": "2025-08-05",
      "has_results": false,
      "last_update_posted_date": "2025-10-15",
      "last_synced_at": "2026-09-17T06:01:39.660Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06273163"
    },
    {
      "nct_id": "NCT04172441",
      "title": "Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Congenital Hyperinsulinism"
      ],
      "interventions": [
        {
          "name": "dasiglucagon",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Zealand Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Days",
        "maximum_age": "364 Days",
        "sex": "ALL",
        "summary": "7 Days to 364 Days"
      },
      "enrollment_count": 12,
      "start_date": "2020-06-19",
      "completion_date": "2022-03-07",
      "has_results": true,
      "last_update_posted_date": "2025-03-14",
      "last_synced_at": "2026-09-17T06:01:39.660Z",
      "location_count": 2,
      "location_summary": "Philadelphia, Pennsylvania • Fort Worth, Texas",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04172441"
    },
    {
      "nct_id": "NCT03856632",
      "title": "Liraglutide Effect in Atrial Fibrillation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Atrial Fibrillation"
      ],
      "interventions": [
        {
          "name": "Liraglutide",
          "type": "DRUG"
        },
        {
          "name": "RFM",
          "type": "OTHER"
        },
        {
          "name": "Anti Arrhythmics",
          "type": "DRUG"
        },
        {
          "name": "Afib Catheter Ablation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2019-03-18",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-09-17T06:01:39.660Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03856632"
    },
    {
      "nct_id": "NCT04330625",
      "title": "Glucagon Receptor Inhibition to Enable Breast Cancer Patients to Benefit From PI3K Inhibitor Therapy (REMD-477)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hyperglycemia Drug Induced"
      ],
      "interventions": [
        {
          "name": "REMD-477",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2020-11-13",
      "completion_date": "2021-05-05",
      "has_results": false,
      "last_update_posted_date": "2022-11-08",
      "last_synced_at": "2026-09-17T06:01:39.660Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04330625"
    },
    {
      "nct_id": "NCT07547878",
      "title": "Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Chronic Kidney Disease",
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Finerenone",
          "type": "DRUG"
        },
        {
          "name": "Semaglutide",
          "type": "DRUG"
        },
        {
          "name": "Lotensin",
          "type": "DRUG"
        },
        {
          "name": "Capoten",
          "type": "DRUG"
        },
        {
          "name": "Enalapril",
          "type": "DRUG"
        },
        {
          "name": "Monopril",
          "type": "DRUG"
        },
        {
          "name": "Lisinopril",
          "type": "DRUG"
        },
        {
          "name": "Univasc",
          "type": "DRUG"
        },
        {
          "name": "Aceon",
          "type": "DRUG"
        },
        {
          "name": "Accupril",
          "type": "DRUG"
        },
        {
          "name": "Altace",
          "type": "DRUG"
        },
        {
          "name": "Mavik",
          "type": "DRUG"
        },
        {
          "name": "Edarbi",
          "type": "DRUG"
        },
        {
          "name": "Atacand",
          "type": "DRUG"
        },
        {
          "name": "Avapro",
          "type": "DRUG"
        },
        {
          "name": "Cozaar",
          "type": "DRUG"
        },
        {
          "name": "Benicar",
          "type": "DRUG"
        },
        {
          "name": "Micardis",
          "type": "DRUG"
        },
        {
          "name": "Diovan",
          "type": "DRUG"
        },
        {
          "name": "Invokana",
          "type": "DRUG"
        },
        {
          "name": "Farxiga",
          "type": "DRUG"
        },
        {
          "name": "Jardiance",
          "type": "DRUG"
        },
        {
          "name": "Ertugliflozin",
          "type": "DRUG"
        },
        {
          "name": "Brenzavvy",
          "type": "DRUG"
        },
        {
          "name": "Sotagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "84 Years",
        "sex": "ALL",
        "summary": "18 Years to 84 Years"
      },
      "enrollment_count": 64,
      "start_date": "2026-04-30",
      "completion_date": "2029-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-08",
      "last_synced_at": "2026-09-17T06:01:39.660Z",
      "location_count": 1,
      "location_summary": "Temple, Texas",
      "locations": [
        {
          "city": "Temple",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07547878"
    },
    {
      "nct_id": "NCT01117350",
      "title": "Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Insulin glargine",
          "type": "DRUG"
        },
        {
          "name": "Liraglutide",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "35 Years to 75 Years"
      },
      "enrollment_count": 978,
      "start_date": "2010-07",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2014-04-11",
      "last_synced_at": "2026-09-17T06:01:39.660Z",
      "location_count": 45,
      "location_summary": "Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 39 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "La Mesa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01117350"
    }
  ]
}